CA-INGRAM-MICRO
Ingram Micro Inc. today announced another wave of financial services to help channel partners solve for the cash crunch created by the COVID-19 pandemic, while meeting the technology needs of businesses and consumers worldwide. Readily available throughout Europe, the new and enhanced Ingram Micro Financial Solutions offerings include flexible, low-interest and long-term financing solutions, as well as extended credit terms, deferred payments, as-a-service models and pay-as-you-go options.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519006025/en/
“Ingram Micro is generating new ways to help our channel partners, and the businesses they serve, stay strong, agile and fiscally smart, so they can come out of this crisis in a position of strength,” said Mark Snider, Executive Vice President and Group President, EMEA, Ingram Micro. “Each country throughout Europe is unique, yet many of our channel partners, and their business customers, face similar fiscal and cash flow concerns, due to the economic impact of COVID-19. Fortunately, financial services are one of the many areas where Ingram Micro is clearly differentiated and able to help our channel partners at scale locally and globally.”
In addition, Ingram Micro is also helping channel partners identify and address the European marketplace’s work from home (WFH) and distance learning requirements, as well as cybersecurity-as-a-service, data centre solutions and cloud-based services. “COVID-19 prioritized digital transformation overnight, placing Ingram Micro and our channel partners in a position to serve and help keep the world securely connected and moving forward together,” Snider continued.
John Mayer, Vice President, Channel Financing, Ingram Micro Europe and Asia Pacific adds, “Our financing options are structured to address the present and give businesses a way to prepare for the future—helping our channel partners and the businesses they serve to create and preserve cash, protect credit lines, and align payments to the current business environment, until business activity is more stable and growing.”
Throughout Europe, channel partners are taking advantage of the new Ingram Micro Financial Solutions programs including the purchase and lease back of IT solutions. “Having the flexibility to lease, buy or defer payments is changing the conversation and allowing us to get our customers the technology they need in real-time without taking on the financial risk or using our own cash to close the deal,” says Ingram Micro channel partner Brian Dunleavy, Commercial Director, Viadex UK Ltd.
Channel partners in Europe can also access longer-term financing solutions through IMFS. These solutions will align payments with revised budget objectives and places the needed capital quickly back into business cash reserves. Similarly, Ingram Micro’s “as a service” finance offerings are making it easier for channel partners interested in expanding their managed services business and cloud practices.
“As-a-service financing solutions are easier on budgets, versus capital-intensive one-time technology purchases. This model also establishes a more profitable recurring revenue stream for channel partners,” says Kris Mees, Vice President Finance and International CFO, Ingram Micro Europe. “With the rising adoption of cloud and managed services, we expect our “as-a-service” financing options to gain more traction, and we’re ready to give channel partners, and the businesses they serve the support they need.”
Additionally, Ingram Micro credit and financial experts are working one-on-one with qualified channel partners across Europe to determine what other offerings may be available to them including custom financing solutions and additional credit capacity. Ingram Micro Europe’s standard suite of financial services and solutions includes:
- Traditional leasing
- Advanced solutions financing
- Managed services financing
- Private-label agreements
- And, financial structures such as fair market value, full pay out, technology equipment rentals, pay-as-you-grow solutions, and guaranteed purchase options
“Today and every day, helping our channel partners understand the financing options available to them and their customers is equally as important as helping them decide on what technology solutions and services are best suited for the needs of their customers,” concludes Mayer. “Together with our channel partners, we will continue to grow and create sustainable business value that leads to an exceptional experience for them and their customers.”
Ingram Micro Financial Solutions operates globally offering financial programs and services across the Americas, Asia Pacific and Europe. To find out more about the financial solutions in Europe, please contact: https://financing.ingrammicro.eu/ .
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unparalleled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519006025/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom